Biotech update from Bret Jensen. http://investorinthefamily.com/   Outperforming market in 2017 after 18 month bear Big uptick in M&A; in Jan   3 big deals   Feb and Mar have been fairly flat Lots of resistance technically   Need an uptick in MA or earnings to break through Expect the uptick to happen in MA   Watch Trump’s actions and not words   Has appointed 2 free market minded people (FDA, Proposed to double fees for drug approval Watching repeal and replace of ACA   Needs to happen before tax and regulatory reform Expect the repeal to happen by April or May     Ocular Therapeutix (OCUL)   Trigger event in July, new product for cataract surgery Insider buying   Omerisk (OMER)   OMS721 Priced at just over $10 w PTs in the $30 Next trigger event in few years   

146 Bret Jensen - Upcoming Catalysts For Biotech (PLUS: 2 Small Cap Picks)

This podcast exists to help you learn to invest and better provide financially for you and your family. 

Currently, we are focusing on building our own, personal Berkshire Hathaway. I'm more excited about this than any other business project I've undertaken. 

Join us only if you're serious about becoming one of the best investors in the world.

Business

Investing

Careers

Management & Marketing

Business News

Shopping

Kirk Spano discusses the coronavirus and it's impact on the US and global economy and what investors can do today to prepare for opportunities to come.

216 - Hoard Cash For The Buying Spree To Come (Kirk Spano)

IBM is down over 30% on the year, does that make it a great buy? The biggest challenge is that of opportunity cost. For those seeking a strong yield with upside potential, Enbridge appears to be a more compelling choice. Brian and Adam discuss the decision making process.

215 - Enbridge: The Reason You Shouldn't Buy IBM (Dividend Sensei)

Oil prices have taken a beating recently and related equities have been hit even harder. Should investors run away or jump and potential opportunities? Kirk and Brian pull the curtain back to see what's really going on and how investors can potentially benefit.

214 - Get Your Portfolio Ready For $80 Oil (Kirk Spano)

NVIDIA recently issued a revenue warning for investors. What's going on? Is this a reason for concern or a great opportunity in hiding? Brian and Mark discuss this and more.

213 - NVIDIA: A Clear Miscalculation (Mark Hibben)

Deflation is the real enemy to fear. Thanks to an aging demographic and soaring debt, it is almost inevitable. In addition, stocks and real estate are greatly overvalued. What's the answer? Kirk and Brian discuss all the above and more. 

146 Bret Jensen - Upcoming Catalysts For Biotech (PLUS: 2 Small Cap Picks)

Download our free app to listen on your phone